<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20240915021345&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20240915021345&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 15 Sep 2024 06:13:46 +0000</lastbuilddate>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The fascinating story of lipid-lowering drugs, sodium-glucose co-transporter 2 inhibitors and GLP1-R agonists: new light shed on their beneficial effects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39276017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 14;45(35):3187-3191. doi: 10.1093/eurheartj/ehae586.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39276017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39276017</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae586>10.1093/eurheartj/ehae586</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39276017</guid>
<pubDate>Sat, 14 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The fascinating story of lipid-lowering drugs, sodium-glucose co-transporter 2 inhibitors and GLP1-R agonists: new light shed on their beneficial effects</dc:title>
<dc:identifier>pmid:39276017</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae586</dc:identifier>
</item>
<item>
<title>Asymptomatic female heterozygous Fabry disease diagnosed through medical check-up</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39271168/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 13:ehae608. doi: 10.1093/eurheartj/ehae608. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39271168/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39271168</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae608>10.1093/eurheartj/ehae608</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39271168</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hiroto Kawamura</dc:creator>
<dc:creator>Kazuto Nakamura</dc:creator>
<dc:creator>Akira Sato</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Asymptomatic female heterozygous Fabry disease diagnosed through medical check-up</dc:title>
<dc:identifier>pmid:39271168</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae608</dc:identifier>
</item>
<item>
<title>Difficulties in running clinical trials on physical activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39271141/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 13:ehae582. doi: 10.1093/eurheartj/ehae582. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39271141/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39271141</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae582>10.1093/eurheartj/ehae582</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39271141</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Emmanuel A Zavalis</dc:creator>
<dc:creator>Pontus Andell</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Difficulties in running clinical trials on physical activity</dc:title>
<dc:identifier>pmid:39271141</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae582</dc:identifier>
</item>
<item>
<title>Clearing up misunderstandings: addressing issues in recent cardiovascular risk review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39271138/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 13:ehae530. doi: 10.1093/eurheartj/ehae530. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39271138/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39271138</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae530>10.1093/eurheartj/ehae530</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39271138</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mina Bakhit</dc:creator>
<dc:creator>Paul Glasziou</dc:creator>
<dc:creator>Magnolia Cardona</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clearing up misunderstandings: addressing issues in recent cardiovascular risk review</dc:title>
<dc:identifier>pmid:39271138</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae530</dc:identifier>
</item>
<item>
<title>Cardiovascular disease risk communication alone is not enough: why a recent review may be misleading</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39271135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 13:ehae529. doi: 10.1093/eurheartj/ehae529. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39271135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39271135</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae529>10.1093/eurheartj/ehae529</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39271135</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sophie Griffiths</dc:creator>
<dc:creator>Brian McMillan</dc:creator>
<dc:creator>Y Kiera Bartlett</dc:creator>
<dc:creator>David French</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular disease risk communication alone is not enough: why a recent review may be misleading</dc:title>
<dc:identifier>pmid:39271135</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae529</dc:identifier>
</item>
<item>
<title>Re-evaluating concurrent training strategies for cardiovascular risk reduction in overweight or obese adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39271133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 13:ehae583. doi: 10.1093/eurheartj/ehae583. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39271133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39271133</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae583>10.1093/eurheartj/ehae583</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39271133</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiawei Du</dc:creator>
<dc:creator>Jinghua Hou</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Re-evaluating concurrent training strategies for cardiovascular risk reduction in overweight or obese adults</dc:title>
<dc:identifier>pmid:39271133</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae583</dc:identifier>
</item>
<item>
<title>Clinical trials in-a-dish for cardiovascular medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39270727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models. In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches including induced pluripotent stem cells (iPSCs). Human iPSCs provide a patient-specific,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 13:ehae519. doi: 10.1093/eurheartj/ehae519. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models. In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches including induced pluripotent stem cells (iPSCs). Human iPSCs provide a patient-specific, precise, and screenable platform for drug testing, paving the way for cardiovascular precision medicine. This review discusses milestones in iPSC differentiation and their applications from disease modelling to drug discovery in cardiovascular medicine. It then explores challenges and emerging opportunities for the implementation of 'clinical trials in-a-dish'. Concluding, this review proposes a framework for future clinical trial design with strategic incorporations of iPSC technology, microphysiological systems, clinical pan-omics, and artificial intelligence to improve success rates and advance cardiovascular healthcare.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39270727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39270727</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae519>10.1093/eurheartj/ehae519</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39270727</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xuekun Wu</dc:creator>
<dc:creator>Kyle Swanson</dc:creator>
<dc:creator>Zehra Yildirim</dc:creator>
<dc:creator>Wenqiang Liu</dc:creator>
<dc:creator>Ronglih Liao</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clinical trials in-a-dish for cardiovascular medicine</dc:title>
<dc:identifier>pmid:39270727</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae519</dc:identifier>
</item>
<item>
<title>Metformin decelerates aging clock in male monkeys</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39270656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>In a rigorous 40-month study, we evaluated the geroprotective effects of metformin on adult male cynomolgus monkeys, addressing a gap in primate aging research. The study encompassed a comprehensive suite of physiological, imaging, histological, and molecular evaluations, substantiating metformin's influence on delaying age-related phenotypes at the organismal level. Specifically, we leveraged pan-tissue transcriptomics, DNA methylomics, plasma proteomics, and metabolomics to develop innovative...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 9:S0092-8674(24)00914-0. doi: 10.1016/j.cell.2024.08.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In a rigorous 40-month study, we evaluated the geroprotective effects of metformin on adult male cynomolgus monkeys, addressing a gap in primate aging research. The study encompassed a comprehensive suite of physiological, imaging, histological, and molecular evaluations, substantiating metformin's influence on delaying age-related phenotypes at the organismal level. Specifically, we leveraged pan-tissue transcriptomics, DNA methylomics, plasma proteomics, and metabolomics to develop innovative monkey aging clocks and applied these to gauge metformin's effects on aging. The results highlighted a significant slowing of aging indicators, notably a roughly 6-year regression in brain aging. Metformin exerts a substantial neuroprotective effect, preserving brain structure and enhancing cognitive ability. The geroprotective effects on primate neurons were partially mediated by the activation of Nrf2, a transcription factor with anti-oxidative capabilities. Our research pioneers the systemic reduction of multi-dimensional biological age in primates through metformin, paving the way for advancing pharmaceutical strategies against human aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39270656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39270656</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.021>10.1016/j.cell.2024.08.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39270656</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuanhan Yang</dc:creator>
<dc:creator>Xiaoyong Lu</dc:creator>
<dc:creator>Ning Liu</dc:creator>
<dc:creator>Shuai Ma</dc:creator>
<dc:creator>Hui Zhang</dc:creator>
<dc:creator>Zhiyi Zhang</dc:creator>
<dc:creator>Kuan Yang</dc:creator>
<dc:creator>Mengmeng Jiang</dc:creator>
<dc:creator>Zikai Zheng</dc:creator>
<dc:creator>Yicheng Qiao</dc:creator>
<dc:creator>Qinchao Hu</dc:creator>
<dc:creator>Ying Huang</dc:creator>
<dc:creator>Yiyuan Zhang</dc:creator>
<dc:creator>Muzhao Xiong</dc:creator>
<dc:creator>Lixiao Liu</dc:creator>
<dc:creator>Xiaoyu Jiang</dc:creator>
<dc:creator>Pradeep Reddy</dc:creator>
<dc:creator>Xueda Dong</dc:creator>
<dc:creator>Fanshu Xu</dc:creator>
<dc:creator>Qiaoran Wang</dc:creator>
<dc:creator>Qian Zhao</dc:creator>
<dc:creator>Jinghui Lei</dc:creator>
<dc:creator>Shuhui Sun</dc:creator>
<dc:creator>Ying Jing</dc:creator>
<dc:creator>Jingyi Li</dc:creator>
<dc:creator>Yusheng Cai</dc:creator>
<dc:creator>Yanling Fan</dc:creator>
<dc:creator>Kaowen Yan</dc:creator>
<dc:creator>Yaobin Jing</dc:creator>
<dc:creator>Amin Haghani</dc:creator>
<dc:creator>Mengen Xing</dc:creator>
<dc:creator>Xuan Zhang</dc:creator>
<dc:creator>Guodong Zhu</dc:creator>
<dc:creator>Weihong Song</dc:creator>
<dc:creator>Steve Horvath</dc:creator>
<dc:creator>Concepcion Rodriguez Esteban</dc:creator>
<dc:creator>Moshi Song</dc:creator>
<dc:creator>Si Wang</dc:creator>
<dc:creator>Guoguang Zhao</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Juan Carlos Izpisua Belmonte</dc:creator>
<dc:creator>Jing Qu</dc:creator>
<dc:creator>Weiqi Zhang</dc:creator>
<dc:creator>Guang-Hui Liu</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metformin decelerates aging clock in male monkeys</dc:title>
<dc:identifier>pmid:39270656</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.021</dc:identifier>
</item>
<item>
<title>Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39269390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The prevalence of diagnosed AF in the United States is higher than previously estimated. More efficient prevention and treatment strategies are needed to curb the burden of AF in the United States.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 19:S0735-1097(24)07903-8. doi: 10.1016/j.jacc.2024.07.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Prevalence estimates of atrial fibrillation (AF) from large populations have not been updated for >;2 decades. Using data from 1996 to 1997, a previous study projected that there would be 3.3 million adults with AF in the United States in 2020.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine the contemporary age-, sex-, and race-standardized prevalence and the number of adults with diagnosed AF in the United States.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We merged California's state-wide health care databases to assemble a cohort of adults aged ≥20 years who received hospital-based care in California from 2005 to 2019. International Classification of Diseases codes were used to identify AF and other comorbidities. After accounting for deaths, we utilized the U.S. Census to calculate the national age-, sex-, and race-standardized estimates of diagnosed AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 29,250,310 patients (mean age 50.6 ± 19.8 years, 53.8% women, 50.1% White), 2,003,867 (6.8%) had an AF diagnosis. The proportion of patients with diagnosed AF increased from 4.49% in 2005 to 2009 to 6.82% in 2015 to 2019. Over time, AF patients became relatively younger, were less likely to be female or White, and were more likely to have hypertension and diabetes. Standardizing based on age-, sex-, race-, and ethnicity-based proportions to the U.S. population, we estimate that the current national prevalence of diagnosed AF is at least 10.55 million (95% CI: 10.48-10.62 million), comprising 4.48% (95% CI: 4.47%-4.49%) of the adult population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The prevalence of diagnosed AF in the United States is higher than previously estimated. More efficient prevention and treatment strategies are needed to curb the burden of AF in the United States.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39269390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39269390</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.014>10.1016/j.jacc.2024.07.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39269390</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jean Jacques Noubiap</dc:creator>
<dc:creator>Janet J Tang</dc:creator>
<dc:creator>Justin T Teraoka</dc:creator>
<dc:creator>Thomas A Dewland</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities</dc:title>
<dc:identifier>pmid:39269390</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.014</dc:identifier>
</item>
<item>
<title>The Alarming Surge of Atrial Fibrillation in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39269389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 5:S0735-1097(24)08158-0. doi: 10.1016/j.jacc.2024.08.009. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39269389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39269389</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.009>10.1016/j.jacc.2024.08.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39269389</guid>
<pubDate>Fri, 13 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Abhishek Deshmukh</dc:creator>
<dc:creator>Siddharth Agarwal</dc:creator>
<dc:creator>Christopher V DeSimone</dc:creator>
<dc:date>2024-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Alarming Surge of Atrial Fibrillation in the United States</dc:title>
<dc:identifier>pmid:39269389</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.009</dc:identifier>
</item>
<item>
<title>TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39265577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>DNA repair and autophagy are distinct biological processes vital for cell survival. Although autophagy helps maintain genome stability, there is no evidence of its direct role in the repair of DNA lesions. We discovered that lysosomes process topoisomerase 1 cleavage complexes (TOP1cc) DNA lesions in vertebrates. Selective degradation of TOP1cc by autophagy directs DNA damage repair and cell survival at clinically relevant doses of topoisomerase 1 inhibitors. TOP1cc are exported from the nucleus...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5:S0092-8674(24)00911-5. doi: 10.1016/j.cell.2024.08.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DNA repair and autophagy are distinct biological processes vital for cell survival. Although autophagy helps maintain genome stability, there is no evidence of its direct role in the repair of DNA lesions. We discovered that lysosomes process topoisomerase 1 cleavage complexes (TOP1cc) DNA lesions in vertebrates. Selective degradation of TOP1cc by autophagy directs DNA damage repair and cell survival at clinically relevant doses of topoisomerase 1 inhibitors. TOP1cc are exported from the nucleus to lysosomes through a transient alteration of the nuclear envelope and independent of the proteasome. Mechanistically, the autophagy receptor TEX264 acts as a TOP1cc sensor at DNA replication forks, triggering TOP1cc processing by the p97 ATPase and mediating the delivery of TOP1cc to lysosomes in an MRE11-nuclease- and ATR-kinase-dependent manner. We found an evolutionarily conserved role for selective autophagy in DNA repair that enables cell survival, protects genome stability, and is clinically relevant for colorectal cancer patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39265577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39265577</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.020>10.1016/j.cell.2024.08.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39265577</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Pauline Lascaux</dc:creator>
<dc:creator>Gwendoline Hoslett</dc:creator>
<dc:creator>Sara Tribble</dc:creator>
<dc:creator>Camilla Trugenberger</dc:creator>
<dc:creator>Ivan Antičević</dc:creator>
<dc:creator>Cecile Otten</dc:creator>
<dc:creator>Ignacio Torrecilla</dc:creator>
<dc:creator>Stelios Koukouravas</dc:creator>
<dc:creator>Yichen Zhao</dc:creator>
<dc:creator>Hongbin Yang</dc:creator>
<dc:creator>Ftoon Aljarbou</dc:creator>
<dc:creator>Annamaria Ruggiano</dc:creator>
<dc:creator>Wei Song</dc:creator>
<dc:creator>Cristiano Peron</dc:creator>
<dc:creator>Giulio Deangeli</dc:creator>
<dc:creator>Enric Domingo</dc:creator>
<dc:creator>James Bancroft</dc:creator>
<dc:creator>Loïc Carrique</dc:creator>
<dc:creator>Errin Johnson</dc:creator>
<dc:creator>Iolanda Vendrell</dc:creator>
<dc:creator>Roman Fischer</dc:creator>
<dc:creator>Alvin Wei Tian Ng</dc:creator>
<dc:creator>Joanne Ngeow</dc:creator>
<dc:creator>Vincenzo D'Angiolella</dc:creator>
<dc:creator>Nuno Raimundo</dc:creator>
<dc:creator>Tim Maughan</dc:creator>
<dc:creator>Marta Popović</dc:creator>
<dc:creator>Ira Milošević</dc:creator>
<dc:creator>Kristijan Ramadan</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival</dc:title>
<dc:identifier>pmid:39265577</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.020</dc:identifier>
</item>
<item>
<title>Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39265576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>The development of successful therapeutics for dementias requires an understanding of their shared and distinct molecular features in the human brain. We performed single-nuclear RNA-seq and ATAC-seq in Alzheimer's disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP), analyzing 41 participants and ∼1 million cells (RNA + ATAC) from three brain regions varying in vulnerability and pathological burden. We identify 32 shared, disease-associated cell types and 14...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 9:S0092-8674(24)00910-3. doi: 10.1016/j.cell.2024.08.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The development of successful therapeutics for dementias requires an understanding of their shared and distinct molecular features in the human brain. We performed single-nuclear RNA-seq and ATAC-seq in Alzheimer's disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP), analyzing 41 participants and ∼1 million cells (RNA + ATAC) from three brain regions varying in vulnerability and pathological burden. We identify 32 shared, disease-associated cell types and 14 that are disease specific. Disease-specific cell states represent glial-immune mechanisms and selective neuronal vulnerability impacting layer 5 intratelencephalic neurons in AD, layer 2/3 intratelencephalic neurons in FTD, and layer 5/6 near-projection neurons in PSP. We identify disease-associated gene regulatory networks and cells impacted by causal genetic risk, which differ by disorder. These data illustrate the heterogeneous spectrum of glial and neuronal compositional and gene expression alterations in different dementias and identify therapeutic targets by revealing shared and disease-specific cell states.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39265576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39265576</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.019>10.1016/j.cell.2024.08.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39265576</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica E Rexach</dc:creator>
<dc:creator>Yuyan Cheng</dc:creator>
<dc:creator>Lawrence Chen</dc:creator>
<dc:creator>Damon Polioudakis</dc:creator>
<dc:creator>Li-Chun Lin</dc:creator>
<dc:creator>Vivianne Mitri</dc:creator>
<dc:creator>Andrew Elkins</dc:creator>
<dc:creator>Xia Han</dc:creator>
<dc:creator>Mai Yamakawa</dc:creator>
<dc:creator>Anna Yin</dc:creator>
<dc:creator>Daniela Calini</dc:creator>
<dc:creator>Riki Kawaguchi</dc:creator>
<dc:creator>Jing Ou</dc:creator>
<dc:creator>Jerry Huang</dc:creator>
<dc:creator>Christopher Williams</dc:creator>
<dc:creator>John Robinson</dc:creator>
<dc:creator>Stephanie E Gaus</dc:creator>
<dc:creator>Salvatore Spina</dc:creator>
<dc:creator>Edward B Lee</dc:creator>
<dc:creator>Lea T Grinberg</dc:creator>
<dc:creator>Harry Vinters</dc:creator>
<dc:creator>John Q Trojanowski</dc:creator>
<dc:creator>William W Seeley</dc:creator>
<dc:creator>Dheeraj Malhotra</dc:creator>
<dc:creator>Daniel H Geschwind</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics</dc:title>
<dc:identifier>pmid:39265576</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.019</dc:identifier>
</item>
<item>
<title>Patching-Up Post-MI Hearts With Microparticle-Delivered Apelin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39265043/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 13;135(7):799-801. doi: 10.1161/CIRCRESAHA.124.325194. Epub 2024 Sep 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39265043/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39265043</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325194>10.1161/CIRCRESAHA.124.325194</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39265043</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Vladislav Leonov</dc:creator>
<dc:creator>Timothy J Kamp</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Patching-Up Post-MI Hearts With Microparticle-Delivered Apelin</dc:title>
<dc:identifier>pmid:39265043</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325194</dc:identifier>
</item>
<item>
<title>Cyclophilin(g) a Knowledge Gap in Heart Failure Pathogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39265042/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 13;135(7):774-776. doi: 10.1161/CIRCRESAHA.124.325132. Epub 2024 Sep 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39265042/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39265042</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325132>10.1161/CIRCRESAHA.124.325132</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39265042</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marion Delaunay</dc:creator>
<dc:creator>Zegeye H Jebessa</dc:creator>
<dc:creator>Timothy A McKinsey</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cyclophilin(g) a Knowledge Gap in Heart Failure Pathogenesis</dc:title>
<dc:identifier>pmid:39265042</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325132</dc:identifier>
</item>
<item>
<title>On the Mend: Atrial Tubulogenesis After Tachypacing-Induced Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39265041/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 13;135(7):755-757. doi: 10.1161/CIRCRESAHA.124.325211. Epub 2024 Sep 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39265041/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39265041</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325211>10.1161/CIRCRESAHA.124.325211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39265041</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michelle L Munro</dc:creator>
<dc:creator>Luis A Gonano</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>On the Mend: Atrial Tubulogenesis After Tachypacing-Induced Heart Failure</dc:title>
<dc:identifier>pmid:39265041</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325211</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39265040/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 13;135(7):706-707. doi: 10.1161/RES.0000000000000692. Epub 2024 Sep 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39265040/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39265040</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000692>10.1161/RES.0000000000000692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39265040</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39265040</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000692</dc:identifier>
</item>
<item>
<title>Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report from the Pulmonary Embolism Research Collaborative</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39263752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of health care, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 12. doi: 10.1161/CIRCULATIONAHA.124.067482. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of health care, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must be routinely monitored to fully capture the impact of modern PE treatment. We set out to standardize data collection in patients with PE undergoing evaluation and treatment, and thus establish the foundation for an expanding evidence base that will address gaps in evidence and inform future care for acute PE. To do so, >;100 international PE thought leaders convened in Washington, DC, in April 2022 to form the Pulmonary Embolism Research Collaborative. Participants included physician experts, key members of the US Food and Drug Administration, patient representatives, and industry leaders. Recognizing the multidisciplinary nature of PE care, the Pulmonary Embolism Research Collaborative was created with representative experts from stakeholder medical subspecialties, including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through the Pulmonary Embolism Research Collaborative, as it is applied to data collection, promises to provide crucial knowledge that will ultimately produce a robust evidence base that will lead to standardization and harmonization of PE management and improved outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39263752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39263752</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067482>10.1161/CIRCULATIONAHA.124.067482</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39263752</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kenneth Rosenfield</dc:creator>
<dc:creator>Terry R Bowers</dc:creator>
<dc:creator>Christopher F Barnett</dc:creator>
<dc:creator>George A Davis</dc:creator>
<dc:creator>Jay Giri</dc:creator>
<dc:creator>James M Horowitz</dc:creator>
<dc:creator>Menno V Huisman</dc:creator>
<dc:creator>Beverley J Hunt</dc:creator>
<dc:creator>Brent Keeling</dc:creator>
<dc:creator>Jeffrey A Kline</dc:creator>
<dc:creator>Frederikus A Klok</dc:creator>
<dc:creator>Stavros V Konstantinides</dc:creator>
<dc:creator>Michelle T Lanno</dc:creator>
<dc:creator>Robert Lookstein</dc:creator>
<dc:creator>John M Moriarty</dc:creator>
<dc:creator>Fionnuala Ní Áinle</dc:creator>
<dc:creator>Jamie L Reed</dc:creator>
<dc:creator>Rachel P Rosovsky</dc:creator>
<dc:creator>Sara M Royce</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:creator>Andrew S P Sharp</dc:creator>
<dc:creator>Akhilesh K Sista</dc:creator>
<dc:creator>Roy E Smith</dc:creator>
<dc:creator>Phil Wells</dc:creator>
<dc:creator>Joanna Yang</dc:creator>
<dc:creator>Eleni M Whatley</dc:creator>
<dc:creator>Pulmonary Embolism Research Collaborative (PERC) Attendees</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report from the Pulmonary Embolism Research Collaborative</dc:title>
<dc:identifier>pmid:39263752</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067482</dc:identifier>
</item>
<item>
<title>Myeloid-Specific JAK2 Contributes to Inflammation and Salt Sensitivity of Blood Pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39263750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings reveal the APC JAK2 signaling pathway as a potential target for the diagnosis and treatment of SSBP in humans.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 12. doi: 10.1161/CIRCRESAHA.124.323595. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Salt sensitivity of blood pressure (SSBP), characterized by acute changes in blood pressure with changes in dietary sodium intake, is an independent risk factor for cardiovascular disease and mortality in people with and without hypertension. We previously found that elevated sodium concentration activates antigen-presenting cells (APCs), resulting in high blood pressure, but the mechanisms are unknown. Here, we hypothesized that APC-specific JAK2 (Janus kinase 2) through STAT3 (signal transducer and activator of transcription 3) and SMAD3 (small mothers against decapentaplegic homolog 3) contributes to SSBP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHOD: We performed bulk or single-cell transcriptomic analyses following in vitro monocytes exposed to high salt and in vivo high sodium treatment in humans using a rigorous salt-loading/depletion protocol to phenotype SSBP. We also used a myeloid cell-specific CD11c<sup>+</sup> JAK2 knockout mouse model and measured blood pressure with radiotelemetry after N-omega-nitro-L-arginine-methyl ester and a high salt diet treatment. We used flow cytometry for immunophenotyping and measuring cytokine levels. Fluorescence in situ hybridization and immunohistochemistry were performed to spatially visualize the kidney's immune cells and cytokine levels. Echocardiography was performed to assess cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that high salt treatment upregulates gene expression of the JAK/STAT/SMAD pathway while downregulating inhibitors of this pathway, such as suppression of cytokine signaling and cytokine-inducible SH2, in human monocytes. Expression of the JAK2 pathway genes mirrored changes in blood pressure after salt loading and depletion in salt-sensitive but not salt-resistant humans. Ablation of JAK2, specifically in CD11c<sup>+</sup> APCs, attenuated salt-induced hypertension in mice with SSBP. Mechanistically, we found that SMAD3 acted downstream of JAK2 and STAT3, leading to increased production of highly reactive isolevuglandins and proinflammatory cytokine IL (interleukin)-6 in renal APCs, which activate T cells and increase production of IL-17A, IL-6, and TNF-α (tumor necrosis factor-alpha).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal the APC JAK2 signaling pathway as a potential target for the diagnosis and treatment of SSBP in humans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39263750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39263750</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323595>10.1161/CIRCRESAHA.124.323595</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39263750</guid>
<pubDate>Thu, 12 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mohammad Saleem</dc:creator>
<dc:creator>Luul A Aden</dc:creator>
<dc:creator>Ashley Pitzer Mutchler</dc:creator>
<dc:creator>Chitra Basu</dc:creator>
<dc:creator>Lale A Ertuglu</dc:creator>
<dc:creator>Quanhu Sheng</dc:creator>
<dc:creator>Niki Penner</dc:creator>
<dc:creator>Anna R Hemnes</dc:creator>
<dc:creator>Jennifer H Park</dc:creator>
<dc:creator>Jeanne A Ishimwe</dc:creator>
<dc:creator>Cheryl L Laffer</dc:creator>
<dc:creator>Fernando Elijovich</dc:creator>
<dc:creator>Celestine N Wanjalla</dc:creator>
<dc:creator>Nestor de la Visitacion</dc:creator>
<dc:creator>Paul D Kastner</dc:creator>
<dc:creator>Claude F Albritton</dc:creator>
<dc:creator>Taseer Ahmad</dc:creator>
<dc:creator>Alexandria P Haynes</dc:creator>
<dc:creator>Justin Yu</dc:creator>
<dc:creator>Meghan K Graber</dc:creator>
<dc:creator>Sharia Yasmin</dc:creator>
<dc:creator>Kay-Uwe Wagner</dc:creator>
<dc:creator>Peter P Sayeski</dc:creator>
<dc:creator>Antonis K Hatzopoulos</dc:creator>
<dc:creator>Eric R Gamazon</dc:creator>
<dc:creator>Alexander G Bick</dc:creator>
<dc:creator>Thomas R Kleyman</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2024-09-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Myeloid-Specific JAK2 Contributes to Inflammation and Salt Sensitivity of Blood Pressure</dc:title>
<dc:identifier>pmid:39263750</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323595</dc:identifier>
</item>
<item>
<title>Atheroimmunology: keeping the immune system in atherosclerosis in check</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39261586/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 11. doi: 10.1038/s41569-024-01075-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39261586/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39261586</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01075-1>10.1038/s41569-024-01075-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39261586</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Claudia Monaco</dc:creator>
<dc:creator>Lea Dib</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Atheroimmunology: keeping the immune system in atherosclerosis in check</dc:title>
<dc:identifier>pmid:39261586</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01075-1</dc:identifier>
</item>
<item>
<title>Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1107-1118. doi: 10.1016/j.jacc.2024.06.038.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized dosing or a change in drug selection. Most evidence supports guiding therapy based on the CYP2C19 allelic variants in patients with an indication for dual antiplatelet therapy. In ticagrelor-treated or prasugrel-treated patients, a genotype-guided de-escalation strategy can reduce bleeding risk, whereas in patients treated with clopidogrel, an escalation strategy may prevent ischemic events. Although the clinical results are promising, few hospitals have implemented these strategies. New results, technological advancements, and growing experience may potentially overcome current barriers for implementation in the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39260933</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.038>10.1016/j.jacc.2024.06.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260933</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Wout W A van den Broek</dc:creator>
<dc:creator>Brenden S Ingraham</dc:creator>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:creator>Craig R Lee</dc:creator>
<dc:creator>Larisa H Cavallari</dc:creator>
<dc:creator>Jesse J Swen</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:39260933</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.038</dc:identifier>
</item>
<item>
<title>Fucosylation: The Prognostic Impact of Sugar in Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39260932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240915021345&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 17;84(12):1104-1106. doi: 10.1016/j.jacc.2024.06.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39260932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240915021345&v=2.18.0.post9+e462414">39260932</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.042>10.1016/j.jacc.2024.06.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39260932</guid>
<pubDate>Wed, 11 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Harrison W Farber</dc:creator>
<dc:creator>Noah C Schoenberg</dc:creator>
<dc:date>2024-09-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fucosylation: The Prognostic Impact of Sugar in Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:39260932</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.042</dc:identifier>
</item>





























</channel>
</rss>